The method of regulating the sex of the offspring of animals

 

(57) Abstract:

The invention relates to animal husbandry, in particular to methods of breeding cattle with the regulation of the sex of the offspring. The method of regulating the sex of offspring in cattle includes intramuscular injection into the body of the cow or heifer prostaglandin F2-alpha in combination with gonadotropin FLC, which is injected selectively into one of the following days after calving: 61st, 65th, 69th, 73rd, 77th and inseminated at a synchronized sexual hunting within 1-7 days after injection of prostaglandin. The invention can be used in the breeding of cattle, primarily in contract matings, aimed at producing sires. The method provides for obtaining offspring to 75.7% bulls. table 1.

The invention relates to animal husbandry, in particular to methods of breeding cattle with the regulation of the sex of the offspring.

The known method of regulating births predominantly female rabbits, based on the electoral damage paleopedology sperms (y chromosome), immune serum on the H-Y antigen. After 8x immunization of female rabbits with antigen, prigotovlenie sperm dead sperm cells and microorganisms and excretion fractions paleopedology sperm. In kN. "Selecciona-genetic methods of increasing the productivity of farm animals": Sa. the scientific. Tr. /Gosagroprom of the USSR, vnpo on plum. case in alive., Grown. select.-Genet. center. -M.: 1987, S. 93). The method provides primary receipt female rabbits. However, its practical use is associated with significant material and labor costs. Furthermore, the method is still not sufficiently developed for use in production.

A known method of regulating the sex of the offspring of cattle, including the introduction into the body of the cow, structuresa amino acids-cysteine mixed with gonadotropin (GSIC). Injection cows gonadotropin FLC, incubated with cysteine for 4 to 10 hours at pH 8 to 9 and a dose of 800 s, intramuscularly was accompanied by an increase in the progeny of the share of bulls to 78%, a 27% higher than in the control. After injection cows gonadotropin FFA in the same dose and also intramuscularly, but pre-incubated with cysteine at pH 5 to 6, in the progeny were mostly heifers - 74%, or 28% more than in the control. the pH of the solution was changed by titration with sulfuric acid or alkali. In all cases, the introduction of gonadotropin FLC was accompanied by injection is modestino steers or heifers. However, he almost never used due to the instability of the results.

When creating the present invention, the task was to develop a method for controlling the sex of offspring of cattle, providing the offspring mainly gobies.

The technical result of the invention is achieved by a method of regulation of the sex of the offspring of cattle, including the introduction into the body of the cow or heifer prostaglandin F2-alpha in combination with gonadotropin FLC. Feature of the proposed method is that the prostaglandin F2-alpha in combination with gonadotropin FLC is injected selectively into one of the following days after calving: 61, 65, 69, 73, 77, and inseminated at a synchronized sexual hunting within 1 to 7 days after injection of prostaglandin. Prostaglandin F2alpha and gonadotropin FLC is injected intramuscularly.

Example. In the experimental farm of Vigée "dubrovitsy" Moscow region 1989 - 1991 144 holsteinian cows with average productivity 5570 kg of milk per year were divided into 4 groups with the timing of injection of prostaglandin F2alpha and gonadotropin FLC from 59 to 78 days after calving. In each groupusa injection of prostaglandin F2alpha and gonadotropin FLC on the 59th, 63rd, 67th, 71st, 75th days after calving; the 2nd group - 60th, 64th, 68th, 72nd and 76th days; in the 3rd group - 61st, 65th, 69th, 73rd and 77th days; 4th group - at the 62nd, 66th, 70th, 74th and 78th days after calving. The animals were injected with drugs intramuscularly according to the scheme: gonadotropin FLC at a dose of 800 I. E. for 4 - 8 hours before or after administration of the prostaglandin F2-alpha in a dose of 0.7 mg (estrofan). The results are presented in the table.

In the progeny of cows 3rd group has been a steady increase in the proportion of calves up to 70-100%, on average, to 75.7% from 37 calves. In the progeny of the 1st group of cows, the proportion of calves was 43.2% from 37 calves, 2-nd and 4-th groups, respectively 45,0 and 48.3% of 40 and 29 calves. The proportion of bulls in the progeny of cows 1st, 2nd and 4th groups ranged from 17 to 72%. The difference with cows 3rd group statistically significant: P<0.01 for groups 1 and 2, and P<0.05 for group 4.

Compared with the prototype of a new way of regulating the sex of the offspring of cattle clinched the bulls 2.3% less (75.7 percent new way and 78% in the prototype). However, the known method is more time consuming (requires incubation gonadotropin-releasing drug at a pH change of the solution) and more expensive (requires additional consumption of materials - acids, alkalis, pH meter). A new way ocii cattle, first of all, in an ordered matings, aimed at obtaining sires.

The method of regulating the sex of the offspring of animals which includes the introduction in the body of females biologically active substances, characterized in that the biologically active substances using prostaglandin F2-alpha in combination with gonadotropin FLC, which is injected into the body of the female cattle selectively in one of the following days after calving: 61st, 65th, 69th, 73rd, 77th and inseminated at a synchronized sexual hunting within 1 to 7 days after injection of prostaglandin.

 

Same patents:

The invention relates to peptide compounds, namely the Decapeptide of formula I: x-X1-X2-X3-Ser-Tyr-X6-Leu-X8-Pro-X10(I), where X is acyl; X1=D-Nal; X2=D-Cpa; X3=D-Рal; X6=D-Cit, D-Hei, D-Orn, D-Lys, D-Neu; X8= Orn, Arg, Lys, L-Neu ; X10= D-AlaNH2, Neu is a residue of formula IX or IV; Z is a group-O - or-S-, n = 1-6
The invention relates to medicine, namely, venereology, obstetrics, gynecology, and can be used to treat women suffering from chlamydia originalnogo tract

The invention relates to the field of biology and medicine and can be used for the treatment of liver injury accompanied by a decrease of the protein synthetic function of the body
The invention relates to medicine, in particular to gynecology
The invention relates to pharmaceutical industry and relates to pharmaceutical preparations which can be used in endocrinology for the treatment of diffuse mastopathy

The invention relates to the field of animal husbandry, in particular to biotechnology animal, to methods of regulating reproductive functions pigs, and can be used to obtain transgenic pigs by injection of genetically engineered structures in the pronuclei of zygotes in research institutions and breeding centers

The invention relates to medicine, in particular to abdominal surgery and relates to a method of autotransplantation of splenic tissue after removal of the spleen

The invention relates to biology, in particular the production of drugs used in animal husbandry and veterinary medicine to stimulate sexual function, stimulation of superovulation for embryo transfer, as well as in endocrine disorders in female farm animals

The invention relates to the compound of formula (I):

< / BR>
where

Ar is chosen from the group including

(a) phenyl, naphthyl and diphenyl, each of which optionally contains from one to three substituents selected from the group including:

C1-4alkyl, C1-4halogenated, C1-4hydroxyalkyl, C1-4alkoxy, C1-4halogenoalkane, C2-4alkoxyalkane, C1-4alkylthio, hydroxy, halogen, cyano, amino, C1-4alkylamino, di (C2-8) alkylamino, C2-6alkanolamine, carboxy, C2-6alkoxycarbonyl, phenyl, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halogenoalkane, cyano group or halogen, phenoxy, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halogenoalkane, cyano and halogen; phenylthio group, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halog is selected from the group including C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halogenoalkane, cyano and halogen;

(b) furyl, benzo (b) furyl, thienyl, benzo/b/thienyl, pyridyl and chenail, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, halogen, C1-4alkoxy, hydroxy, phenyl, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halogenoalkane, cyano or halogen, phenoxy group, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halogenoalkane, cyano group and halogen; phenylthio group, optionally containing from one to three substituents selected from the group comprising C1-4alkyl, C1-4halogenated, C1-4alkoxy, C1-4halogenoalkane, cyano and halogen

The invention relates to veterinary medicine, in particular, to methods of treatment of endometritis in cows using medicinal product prepared from peracetic acid-desoxin, in combination with the organic active substances

The invention relates to medicine, in particular to Oncology, and for the treatment of metastatic tumors

The invention relates to medicine and the development of drugs that improve blood circulation

The invention relates to a tool to slow down platelet aggregation, clerk for inhibition of platelet function and for the treatment of thrombosis, containing carbacyclin derivatives-cicaprost or eptalofos and acetylsalicylic acid (hereinafter ASS)

The invention relates to organic chemistry, specifically to new biologically active compounds derived from polyunsaturated fatty acids, hydroxypregnenolone fatty acids and prostaglandins of General formula I:

< / BR>
where R the rest prostaglandin formula:

< / BR>
where one of the two groups at C-9 atom (R1or R2) a hydrogen atom, and the other hydroxyl (R2or R1or R1and R2together form a keto or hydroxyimino; and where one of the two groups at C-11 of the atom (R3or R4) a hydrogen atom, and the other hydroxyl (R4or R3or R3and R4together form a keto or hydroxyisopropyl; provided that R3and R4do not form a keto or hydroxyisopropyl when R1and R2together form a keto or hydroxyimino; and where one of the two groups at C-15 atom (R5or6) a hydrogen atom, and the other (R6or R5) hydroxyl or fluorine atom; the symbolrepresents a single or a CIS-double bond; or R is the residue of a prostaglandin of the formula:

represents a single or double bond, provided that R7or R8do not form a hydroxyl, when the C-10 and C-11 atoms connected by a double bond, or provided that if7or R8hydroxyl, C-12 and C-13 atoms are connected by the TRANS-double bond; and where one of the two groups at C-15 atom (R9or R10) a hydrogen atom, and the other (R10or R9) hydroxyl;

or R the rest of the prostaglandin type I formula:

< / BR>
where the group Q at C-5 of the atom the atom is iodine or bromine, the symbolrepresents a single or double bond, provided that Q is bromine or iodine, when the C-5 and C-6 atoms connected by a double bond;

or R residue of the unsaturated fatty acids of the formula:

< / BR>
where a 0 6, f 1 6, 1 7, provided that the total carbon chain length from 18 to 22 carbon atoms;

or R residue hydroxy acid of the formula:

< / BR>
where m 1 7 x 0 4, k 0 4, n is 0 to 3, provided that the total carbon chain length from 18 to 22 carbon atoms, and str is

The invention relates to gastroenterology

The invention relates to medicine and can be used to treat conditions involving increased adhesion - aggregation of platelets and for preservation of platelet-rich plasma
Up!